(833) 227-6773 
info@acpmp.org 
751 Sproul Road #1057, Springfield, PA 19064 On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (brand name Rasonque), a new targeted therapy that blocks multiple forms of the RAS protein, for adults with metastatic pancreatic cancer.
About the approval
Daraxonrasib is a once-daily pill developed by Revolution Medicines. It is approved for adults with metastatic pancreatic adenocarcinoma who have already received at least one prior systemic therapy, or who are not candidates for multi-drug chemotherapy.
The approval was based on a clinical trial of 500 patients. Patients who received daraxonrasib lived a median of 13.2 months, compared with 6.7 months for those who received standard chemotherapy.
Why this matters for appendix cancer
Although this approval is specifically for pancreatic cancer, it is highly relevant to appendix cancer research. KRAS/RAS mutations are common in appendiceal cancers, particularly the mucinous subtypes. Experts note that the new generation of KRAS-directed drugs has potential relevance for appendix cancers that carry these mutations.
Daraxonrasib is not currently approved for appendix cancer. However, research into RAS-targeted treatments for appendix cancer is moving quickly, including laboratory studies and early patient experience reported by appendix cancer researchers, and clinical trials designed specifically for appendix cancer patients are being developed.
What patients can do
Patients may wish to ask their care team whether tumor genomic sequencing has been done and whether their cancer carries a KRAS mutation. Keep an eye on ACPMP’s Clinical Trials Database for new studies, and explore related research in our Published Research library.
Learn more
This summary is for general information only and is not medical advice. Please talk with your care team about what this research may mean for you.